Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label rats. Show all posts
Showing posts with label rats. Show all posts

Tuesday, August 25, 2026

A Novel Curcumin-Based Formulation Offers Protection Against Neurodegeneration in Rat Models of AlCl3 Induced Alzheimer’s Disease

 How long will it take for your competent? doctor/hospital to get human testing going for stroke related neurodegeneration? NEVER? So your stroke medical 'professionals' are useless?

Do you prefer your doctor, hospital and board of director's incompetence NOT KNOWING? OR NOT DOING? Your choice; let them be incompetent or demand action!

 A Novel Curcumin-Based Formulation Offers Protection Against Neurodegeneration in Rat Models of AlCl3Induced Alzheimer’s Disease

Mohamed Arif1*, V. Gayathri2, Radhika Ravindran3,P. Kalaivani2, R. Siva2, Shonam Tamrakar2 1Gidaa Life Sciences Private Limited, 287, 9th Cross, Bapuji Layout Near Chandra Layout, Vijayanagara, Bangalore, Karnataka 560040, India. 2Centre for Toxicology and Developmental Research, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), No. 1, Ramachandra Nagar, Porur, Chennai 600116, Tamil Nadu, India. 3Tissue Engineering and Biomaterials Lab, Department of Biotechnology, IIT Madras, India. *Corresponding Author: Mohamed Arif, Gidaa Life Sciences Private Limited, 287, 9th Cross, Bapuji Layout Near Chandra Layout, Vijayanagara, Bangalore, Karnataka 560040, India. DOI: https://doi.org/10.58624/SVOANE.2026.07.030 Received: July 31, 2026 Published: August 18, 2026 Citation: Arif M, Gayathri V, Ravindran R, Kalaivani P, Siva R, Tamrakar S. A Novel Curcumin-Based Formulation Offers Protection Against Neurodegeneration in Rat Models of AlCl3-Induced Alzheimer’s Disease. SVOA Neurology 2026, 7:4, 220-238. doi.org/10.58624/SVOANE.2026.07.030 

 Abstract 


The exact mechanisms underlying Alzheimer’s disease (AD) pathogenesis are not fully understood, and effective disease-modifying treatments remain lacking despite decades of AD research. Therefore, alternative therapeutic approaches that may target multiple mechanisms of action underlying AD and have a better safety profile than synthetic drugs, such as phytotherapy, are being explored. We aimed to assess the neuroprotective properties of a novel curcumin formulation fortified with andrographolides and piperine (MAG XXI) in rat models of aluminium chloride–induced AD. Overall, 30 male Wistar rats were included and divided into five groups (a healthy control group, a non-treated AD group, and three AD groups treated with donepezil or 200/400 mg/kg body weight of MAG XXI). The Morris water maze, passive avoidance, and elevated plus maze tests were performed on the rats. Tissue samples from the cortex and hippocampus of the rats were then subjected to biochemical evaluation of neuronal, oxidative stress, and inflammatory markers. Compared to non-treated rats, donepezil-treated rats and high-dose (400 mg/kg body weight) MAG XXI–treated rats showed a mild but significant improvement in the Morris water maze and elevated plus maze test findings and a marked and significant improvement in the passive avoidance task results. Furthermore, oxidative stress markers, inflammatory markers, and neuronal markers improved overall in the donepezil-treated group and in both MAG XXI–treated groups. Notably, the improvement in the oxidative stress markers was more marked with MAG XXI (both doses) than with donepezil. Histopathological examination revealed lower incidence rates of neurofibrillary tangles, gliosis, and neuronal degeneration in the high-dose MAG XXI and donepezil groups. Notably, cresyl staining revealed minimal-to-mild cell dispersion in the donepezil group, whereas normal neuronal cells with well-lineated cell bodies and Nissl substance were observed in the high dose MAG XXI group. No adverse events were noted in the MAG XXI groups. MAG XXI could be a promising alternative for AD treatment because it appears to exhibit neuroprotective properties, as demonstrated by its ability to alleviate oxidative stress and neuroinflammation. However, further clinical trials involving humans are necessary to corroborate the present study’s results

Tuesday, July 21, 2026

This Russian Peptide Regrew Brain Cells in Stroke Rats. The Human Data Is Thin But the Safety Record Spans 3 Decades

 Three decades of incompetence in your doctor and hospital in not getting this to an interventional protocol! Aren't you glad of WORLD CLASS INCOMPETENCE in your facility?

 Of course your competent? doctor already has EXACT PROTOCOLS that deliver all the BDNF you need. And has been for over a decade, right? But your doctor incompetently knew nothing and did nothing, right? Which means your board of directors is so incompetent they can't recognize incompetence in their staff!

  • BDNF (209 posts to April 2011)

This Russian Peptide Regrew Brain Cells in Stroke Rats. The Human Data Is Thin But the Safety Record Spans 3 Decades

A clear pill that lets you read a book in 15 minutes and actually remember it. Learn Italian over a weekend. Use that new skill to charm an Italian supermodel you can now understand both literally and emotionally.That’s the pitch of the movie Limitless, where Bradley Cooper transforms from washed-up writer to Wall Street genius after taking a designer drug.Society has chased chemical brain boosters for over a century. World War II literally ran on speed—Germans had Pervitin (methamphetamine they nicknamed “tank chocolate”), while Allies distributed Benzedrine, basically 1940s Adderall.

The Air Force fed pilots “go pills”—pure dextroamphetamine—from Vietnam through Afghanistan, which may have contributed to a 2002 incident where two US pilots on Dexedrine accidentally bombed a Canadian unit.

The pattern never changes: every shortcut works, but every shortcut bills you—whether it’s your heart, sleep, or addiction risk.

Enter Soviet Neuroscience

Semax is a heptapeptide—seven amino acids strung together: methionine, glutamate, histidine, phenylalanine, proline, glycine, and proline.

Unlike other peptides extracted from animal tissue, Semax was designed on purpose by Soviet pharmacologists at Moscow’s Institute of Molecular Genetics starting in the 1980s.

Researchers started with a fragment of ACTH (adrenocorticotropic hormone), which normally tells adrenal glands to produce cortisol. A four-amino-acid fragment showed positive stress effects on brain function—think learning, attention, resistance to low oxygen—without hormonal downsides like muscle breakdown.

Scientists welded on a proline-glycine-proline tail to prevent enzymatic degradation, creating a brain-targeted stress hormone fragment with built-in stabilizer. A non-stimulant cognitive booster with no obvious addiction profile—exactly what everyone had been hunting for.

At roughly 814 daltons, Semax is relatively small (BPC-157 is about 1,419, semaglutide exceeds 4,000). Small enough that Russians believed nasal mucous membranes could deliver it directly to brain tissue—hence the nasal drop delivery method.

How Semax Actually Works

The headline mechanism involves BDNF—brain-derived neurotrophic factor. Think of it as fertilizer for neurons, helping them survive, connect, and rewire.

In rat studies, Semax increases BDNF and its receptor TrkB in hippocampus and forebrain. That’s the most coherent thread in Semax research and the basis for every neuroplasticity claim attached to it.

It also nudges monoamine neurotransmitters like dopamine and serotonin. But here’s critical nuance matching user reports: Semax is not a stimulant.

In rat studies, Semax alone barely moved dopamine but amplified response when something else was already driving it. That’s why most users describe feeling more motivation rather than a true buzz.

It’s Not NZT

The entire Limitless premise builds on the myth that we only use a fraction of our brains. Unfortunately, that’s fiction—we’re already using essentially 100% of our brains at baseline.

Semax doesn’t unlock dormant capacity waiting for activation. It optimizes signaling in tissue you’re already running.

What Does Science Actually Show

The evidence is present but lopsided in a very specific way.

Bench and animal data is surprisingly deep. Cell studies show BDNF and nerve growth factor genes activating. Rat stroke research is strongest—researchers literally tied off brain arteries in rats, administered Semax, then watched gene expression shift from inflammatory/injury patterns toward repair.

One study showed boosted cell proliferation in injured rat brains, spawning online claims that “Semax regrows your brain.” But again, this is in mice—not 35-year-old humans trying to focus on Excel spreadsheets.

Human Data Is Thin and Russian

A small fMRI study showed intranasal Semax measurably changed brain network activity in healthy volunteers. Older EEG and cognitive work from the 1990s exists, plus a stroke rehab study where Semax plus early rehabilitation raised blood BDNF and slightly accelerated recovery.

But large placebo-controlled trials examining cognitive improvements—how most people actually use it—are still lacking.

Russia has used Semax as an approved drug for over 30 years in stroke patients, giving it more real-world data than almost any non-FDA-approved substance. While not as robust as semaglutide trials, in some ways it’s better—GLP-1 agonists haven’t been around nearly as long.

Semax’s efficacy as cognitive booster may be fuzzy, but its safety profile appears solid.

Dosing: Russian Medicine vs. Gray Market

Russian pharmaceutical Semax comes as nasal drops in two strengths: 0.1% solution for cognitive boost and stroke recovery, and stronger 1% reserved for acute hospital stroke treatment.

One drop of 0.1% delivers approximately 50 micrograms. Labeled daily range runs from a few hundred up to couple thousand micrograms, usually for only a few days at a time.

Gray market biohackers report using nasal sprays between 100-1,000 micrograms daily, typically 5 days on, 2 days off, because tolerance develops quickly and spray isn’t cheap.

Some insist they get better results from subcutaneous injection, though this has no obvious upside and adds another needle to weekly routine.

The Gray Market Problem

When buying “research use only” Semax, there’s decent chance you’re not buying Semax itself. There’s an entire family of remixes: N-acetyl Semax and N-acetyl Semax amidate (Adamax), each with chemical tweaks to extend half-life or intensify effects.

Those aren’t the molecules from Russian studies. Your mileage may vary—like buying a live bootleg concert recording where maybe it sounds better than studio version, or maybe the artist is drunk and slurring.

Side Effects and Safety

Semax is generally well-tolerated, which is major part of its appeal. But well-tolerated doesn’t mean risk-free.

Common user-reported complaints include:

  • Anxiety and irritability
  • Headaches
  • Nausea
  • Insomnia if taken late in day
  • Unpleasant emotional intensity—like volume got cranked on whatever you were already feeling

The single most common complaint? Feeling absolutely nothing, even at high doses. Could mean bad product, incomplete absorption, wrong analog, or simply individual non-response.

Russian labeling contraindicates pregnancy, breastfeeding, acute psychiatric illness, and notably, history of seizures. Anything nudging brain excitability deserves respect—”naturally derived peptide” doesn’t automatically mean benign.

The scariest thing about Semax in the USA isn’t the peptide itself—it’s the bottle. Since it can’t be legally manufactured here for human consumption, there’s zero guarantee regarding purity, sterility, or whether labeled dose matches actual contents.

FDA Meeting Could Change Everything

On July 23-24, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) meets to decide the fate of several peptides, including Semax.

BPC-157, KPV, TB-500, and MOTS-c are up day one. Semax joins Epitalon and Dihexa on day two, July 24th.

These peptides exist in regulatory limbo. This meeting decides whether they return to a list allowing compounding pharmacies to legally manufacture them under real oversight with quality control, or stay banished to gray market forever.

For Semax specifically, the committee reviews it for cerebral ischemia and trigeminal neuralgia. While PCAC votes are technically advisory, FDA won’t grant access to legitimate high-quality Semax from compounding pharmacies without it.

There’s a public comment docket at regulations.gov that committee members must consider. Comments submitted by July 9th get physically handed to committee before the meeting. After that deadline, FDA may still read them, but people casting votes won’t see them.

The Real Limitless Pill

Is Semax a real-life limitless pill? Probably not. We’re still waiting for actual NZT, and nothing flips your brain to 100% because you’re already running at 100%.

Remember how Limitless actually ends: even fictional NZT had a body count—tolerance, blackouts, withdrawal, people dying when supply runs dry. Even the fantasy came with a bill.

But is Semax a real molecule with genuine cognitive effects, legitimate neuroprotective properties, and 30 years of Russian clinical use? Absolutely. It emerged from legitimate pharmaceutical research in Moscow, not a Hollywood writer’s room.

Semax may be subtle and context-dependent, but positive signals appear exactly where they matter—in cognition and the injured, stressed brain.

Your Real NZT Already Exists

For those chasing focus, the closest thing to a real-life limitless pill is less exciting than movie trailers but costs nothing: sleep, blood pressure control, exercise, avoiding alcohol, treating sleep apnea, addressing depression.

That’s your NZT. Once those fundamentals are dialed, Semax might be reasonable value-add. But it isn’t the whole meal.

When fundamentals are out of whack, nothing else does the work for you. The fanciest Russian nasal spray on Earth will likely be one big expensive disappointment.

Semax is a real molecule with real effects and genuine potential—but it’s a tool, not magic. And if you want access to properly manufactured versions with quality control, make your voice heard at the FDA docket before July 9th.

Monday, May 25, 2026

Quinoa seed (Chenopodium quinoa W.) extract attenuates Alzheimer’s disease–like neurodegeneration: Targeting the SLC7A11/GPX4 pathway

Attenuates: Medicine & Biology: To make a virus or bacteria less virulent or harmful. You really think your competent? doctor and hospital will get human testing going?

Quinoa seed (Chenopodium quinoa W.) extract attenuates Alzheimer’s disease–like neurodegeneration: Targeting the SLC7A11/GPX4 pathway

Abstract

Background

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and hippocampal neuronal loss. Targeting ferroptosis-related pathways represents a promising therapeutic strategy.

Objective

This study aimed to investigate the potential effect of quinoa (Chenopodium Quinoa W.) seed extract in an aluminum chloride (AlCl₃)–induced rat model of AD, with a particular focus on the SLC7A11/GPX4 antioxidant axis and NCOA4-mediated ferritinophagy.

Methods

Adult male rats were randomly divided into four groups (n = 6): GI (Control), GII (AD), GIII (Quinoa + AD), and GIV (Alzemenda + AD). AD was induced by oral AlCl₃ administration. Quinoa extract and Alzemenda were administered concurrently with AlCl₃ throughout the experimental period. Behavioral performance was evaluated using the Morris Water Maze and Open Field Test. Oxidative stress markers, iron parameters, gene expression, and histopathological changes in the hippocampus were assessed.

Results

GII exhibited significant cognitive impairment, increased lipid peroxidation, depletion of antioxidant defenses, downregulation of SLC7A11, and marked hippocampal iron deposition compared with GI. Treatment with quinoa (GIII) significantly improved learning and memory, restored GPX4 activity and GSH levels, upregulated SLC7A11 expression, and attenuated hippocampal iron deposition. GIV showed comparable behavioral and histological improvement. Systemic iron indices, as well as hippocampal FPN1 and NCOA4 expression, did not differ significantly among groups.

Conclusion

Quinoa seed extract exerts ameliorating effects in AlCl₃-induced AD by suppressing oxidative stress-associated neurodegeneration through preservation of the SLC7A11/GSH/GPX4 axis rather than modulation of iron export or ferritinophagy pathways.

 This is a preview of subscription content, log in via an institution  to check access.

Saturday, May 9, 2026

Atractylodin alleviates neuroinflammation and protects neurological function after ischemic stroke in association with reduced NLRP3 inflammasome activation

 Your competent? doctor and hospital will need to get human testing going THAT ALSO CREATES EXACT REHAB PROTOCOLS!

Do you prefer your doctor, hospital and board of director's incompetence NOT KNOWING? OR NOT DOING? Your choice; let them be incompetent or demand action!

Atractylodin alleviates neuroinflammation and protects neurological function after ischemic stroke in association with reduced NLRP3 inflammasome activation


  • 1. College of Basic Medical Sciences, China Three Gorges University, Yichang, Hubei, China

  • 2. Nanyang Second General Hospital, Nanyang, Henan, China

Abstract

Background:

NOD-like receptor protein 3 (NLRP3) inflammasome–driven neuroinflammation contributes to ischemic stroke injury. Atractylodin (ART) shows anti-inflammatory activity, but its neuroprotective potential and mechanistic links to NLRP3 signaling after cerebral ischemia–reperfusion (I/R) injury remain to be defined.


Materials and methods:

BV2 microglia were subjected to oxygen–glucose deprivation/reoxygenation (OGD/R), and rats underwent middle cerebral artery occlusion (MCAO) followed by reperfusion. ART was administered after reperfusion in vivo (10 or 30 mg/kg, once daily for 3 days) and during reoxygenation in vitro. Neurobehavioral outcomes and infarct volume were assessed in MCAO rats, along with measurements of neuronal apoptosis. NLRP3 inflammasome activation, gasdermin D (GSDMD)–dependent pyroptosis, pro-inflammatory cytokines, and microglial polarization markers were evaluated using immunoblotting, immunofluorescence, RT-qPCR, and enzyme-linked immunosorbent assay (ELISA).


Results:

In OGD/R-stimulated BV2 microglia, ART suppressed NLRP3 inflammasome activation and reduced GSDMD cleavage, accompanied by decreased IL-1β and IL-18 production. In the MCAO model, ART significantly improved neurological outcomes and reduced infarct volume and neuronal apoptosis. These protective effects were linked to a reduction in the expression of NLRP3 pathway components (NLRP3, ASC, and caspase-1) and GSDMD-N. Additionally, there was a shift in microglial responses toward an anti-inflammatory (M2-like) profile, which led to a decrease in pro-inflammatory markers.


Conclusion:

ART confers neuroprotection in experimental ischemic stroke by inhibiting NLRP3 inflammasome–associated pyroptosis and modulating microglial inflammatory polarization, supporting its potential as a therapeutic candidate for ischemic stroke.


More at link.

Thursday, April 16, 2026

Clemizole Mitigates Traumatic Brain Injury by Inhibiting Oxidative Stress, Neuroinflammation, and Apoptosis

 Will anyone in stroke actually think of and do human testing of this for stroke? Of course not, there aren't two functioning neurons anywhere in stroke!

Do you prefer your doctor, hospital and board of director's incompetence NOT KNOWING? OR NOT DOING? Your choice; let them be incompetent or demand action!

OH NO! your doctor KNOWS NOTHING AND DOES NOTHING! 

Clemizole Mitigates Traumatic Brain Injury by Inhibiting Oxidative Stress, Neuroinflammation, and Apoptosis

 Chandan Chauhan 
Paarth Kumar 
Harapriya Baral 
Tara Datt Bhatt 
Joydev K. Laha 
Maneesh Kashyap 
Ravinder K. Kaundal

Abstract

Abstract Image

Traumatic brain injury (TBI) triggers complex secondary pathological mechanisms, including neuroinflammation, oxidative stress, and apoptosis, contributing to long-term cognitive and motor deficits. This study investigates the neuroprotective potential of Clemizole, a known TRPC5 inhibitor, in a weight-drop rat model of TBI. Target prediction analyses using Swiss Target Prediction and CTD databases identified 159 overlapping genes between Clemizole and TBI. Protein–protein interaction network and hub gene analyses highlighted key proteins, such as TNF-α, CASP3, MMP-9, and TRPC5, implicating them in TBI pathogenesis. KEGG pathway enrichment revealed Clemizole-targeted pathways, including PI3K-Akt, TNF signaling, and apoptosis. After TBI, behavioral assessments showed that Clemizole significantly improved neurological scores, grip strength, locomotor activity, and spatial learning deficits. Biochemical assays revealed that Clemizole dose-dependently reduced nitrite and MDA levels while restoring GSH, indicating attenuation of oxidative stress. H&E (hematoxylin and eosin) and cresyl violet staining confirmed reduced neuronal degeneration and preserved cortical integrity. Clemizole also downregulated inflammatory cytokines and glial markers (Iba-1 and GFAP), alongside restoring BBB integrity via upregulation of tight junction proteins and suppressing MMP-9 expression. Furthermore, Clemizole activated the PI3K-Akt signaling pathway, decreasing the expression of pro-apoptotic proteins (Bax, caspase-9 and caspase-3) and restoring Bcl-2 levels. Importantly, Clemizole decreased TRPC5 expression and attenuated CHOP-mediated ER stress, suggesting a mechanistic link between TRPC5 inhibition and PI3K-Akt-mediated neuroprotection. Collectively, these findings demonstrate that Clemizole confers multifaceted neuroprotection following TBI by targeting TRPC5-mediated calcium dysregulation, restoring PI3K-Akt signaling, and attenuating oxidative, inflammatory, and apoptotic cascades. This study identifies Clemizole as a promising therapeutic candidate for mitigating secondary brain injury and promoting functional recovery after TBI.

© 2026 American Chemical Society

Tuesday, April 7, 2026

Copper depletion ameliorates neuronal damage after intracerebral hemorrhage

 Will your competent? doctor DO ANYTHING AT ALL WITH THIS?

NO? So, doesn't care about your recovery at all! Won't get human testing going either?

Do you prefer your doctor, hospital and board of director's incompetence NOT KNOWING? OR NOT DOING? Your choice; let them be incompetent or demand action!

OH NO! your doctor KNOWS NOTHING AND DOES NOTHING! 

Copper depletion ameliorates neuronal damage after intracerebral hemorrhage


https://doi.org/10.1016/j.neuint.2026.106150Get rights and content
Under a Creative Commons license
Open access

Highlights

  • Intracerebral hemorrhage (ICH) induces copper overload and cuproptosis in perihematomal brain tissue.
  • The copper chelator TTM mitigates copper accumulation and inhibits cuproptosis in vivo and in vitro.
  • Copper depletion with TTM alleviates ICH-induced brain injury and neuronal death.
  • TTM treatment promotes the expression of neurite regeneration-associated proteins GAP43 and MAP2.
  • Targeting copper-induced cuproptosis is a promising therapeutic strategy for ICH.

Abstract

Background

Intracerebral hemorrhage (ICH) is a severe subtype of stroke. There are currently no specific treatment strategies for secondary brain injury and neurological deficits following ICH. Copper (Cu) is an essential cofactor for all living organisms. Cytotoxicity can occur when copper ion concentration exceeds the homeostatic threshold, leading to cell death. However, the relationship between copper and ICH is unclear.

Methods

In vivo, an ICH model was established in male Sprague-Dawley rats by stereotactically injecting autologous blood into the right basal ganglia. In vitro, we employed hemin and CuCl2 to simulate ICH conditions and induce cuproptosis in BV2 microglial cells. To investigate the role of copper in brain injury and neuronal damage, we administered the copper chelator tetrathiomolybdate (TTM) and knocked down the essential cuproptosis gene ferredoxin 1 (FDX1).

Results

Our findings demonstrate that following ICH, elevated copper levels and FDX1 expression, low expression of lipoylated dihydrolipoamide S-acetyltransferase (DLAT) and lipoic acid synthetase (LIAS), loss of mitochondrial membrane potential and neuronal impairment (increased growth associated protein 43 (GAP43) and decreased microtubule associated protein 2 (MAP2) expression), ultimately lead to neuronal death. Both TTM and si-FDX1 treatment attenuated the copper overload and inhibited cuproptosis, thereby ameliorating the ICH-induced phenotype.

Conclusion

Copper depletion attenuates ICH-induced neuronal damage by inhibiting cuproptosis, highlighting a potential therapeutic strategy for mitigating secondary brain injury and neuronal damage following ICH.